anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A number of aryl semicarbazones were prepared as candidate anticonvulsants. When administered orally to rats, significant activity was noted in the maximal electroshock (MES) screen and since neurotoxicity was either absent or reduced (as compared to intraperitoneal injection in mice), high protection indices were found in the majority of the compounds. The semicarbazones displayed little or no activity in the subcutaneous pentylenetetrazol screen. These observations support the theory that one large hydrophobic group (in this case the aryl ring) are requirements for protection in the MES screen. In general, the semicarbazones had rapid onsets of action and the most common mechanism of action was interaction with chloride channels. Empirical and semi-empirical conformational calculations indicated that certain molecular fragments and hydrophobicity of these molecules affect bioactivity.
COVID-19+ patients over age 16 admitted to acute care hospitals, GIM/other wards of participating hospitals will be invited to participate. Patients who were hospitalized prior to this study start up (from January 25, 2020 to study start up) will be invited to participate in this study.
The inventors has developed a recombinant molecular system, named OptoFab, allowing the accurate control of the agonistic properties of an antibody-derived Fab fragment in time and in space using specific wavelengths of light. It consists in a Fab fragment derived from an agonistic antibody of interest, linked to optogenetic modules that confer a light response capacity. Indeed, antibody derived Fab fragments generally keep the specificity of the antibody for its epitope, but not its agonistic properties. However, when Fab fragments are oligomerized, they recover the agonistic properties of the whole antibody. These characteristics, are at the basis of the OptoFab concept as its objective is to manipulate the oligomerization/immobilization statue of a Fab fragment using optogenetics to control its agonistic property. The present invention relates to methods and systems for controlling the agonistic properties of antibody variable domains by light.
PROBLEM TO BE SOLVED: To decrease the endotoxin content to below a specific level by subjecting raw oil and fat to a non-heating treatment for removing endotoxin. SOLUTION: The content of endotoxin in oil and fat is decreased to not more than 20 EU/g. The non-heating treatment for removing endotoxin is carried out by filtration by means of a filtration support. The filtration support used is preferably one modified with a positive charge. The filtration support modified with a positive charge comprises a filtration support, formed of cellulose, nylon, agarose, polystyrene or the like, subjected to fixation of a positively charged electrolyte such as a compound or the like bearing an amino group, introduction of an amino acid group, fixation of histidine, or the like. As the filtration support modified with a positive charge are exemplified Zetapore, Zetaplus or the like. The shape of the filtration support itself is not particularly limited, but preferably film-like, porous resin-like or fiber-like.  The pore size is about 0.2-10 μm, preferably 0.2-0.5 μm.
PURPOSE:To provide a ceramic frame for a crown in place of a metal cast frame by setting alumina and leucite to a main crystal phase. CONSTITUTION:When alumina and leucite are set to a main crystal phase, a pref. coefficient of linear expansion is provided to the ceramic material used in a conventional alloy cast frame as a building-up material and, therefore, a process building up and baking a usual ceramic material can be adapted. This ceramic material is white in its hue and easily colored by commercial pigment and built up as the substrate of the usual ceramic material as it is without using a shield material to make it possible to obtain a pref. hue. As mentioned above, the ceramic material generally used on the spot of dental treatment can be adapted and a manufacturing utensil for building up the ceramic material or baking the same can be used and a ceramic frame for a crown having a pref. coefficient of linear expansion as the substrate of the ceramic material and high mechanical strength and excellent in bio-compatibility and corrosion resistance can be provided in place of the alloy cast frame.
Phospholipid compositions are obtained from ground. homogenised animal organs by a four stage process. in the first stage the organs are soaked in acetone to sever bonds between phospholipids and other substances present in the organ. In the second stage, the organs are refluxed in acetone to remove extraneous matter such as proteins and amino acids. In the third stage, the phospholipids are extracted with ethanol. The acetone solutions, which may contain small amounts of entrained phospholipids, and the ethanol solution are all evaporated to dryness and the residues are taken up in diethyl ether. In the fourth stage the phospholipids are precipitated by addition of acetone. The phospholipid compositions obtained are of sufficient purity for pharmaceutical use.
PURPOSE:To obtain a percutaneous absorbefacient, consisting of monocaprylic acid ester of glycols and capable of promoting percutaneous absorption of various drugs, enhancing permeability of the drugs from the skin by containing thereof together with the drugs in a pharmaceutical and providing an excellent blood level of the drugs. CONSTITUTION:A percutaneous absorbefacient consisting of monocaprylic acid ester of glycols, e.g. ethylene glycol monocaprylate or polypropylene glycol monocaprylate. The above-mentioned compound is directly used or dissolved, dispersed or suspended in a suitable solvent, such as water or lower alcohols, and used for preparing a pharmaceutical. If ethanol or propanol is especially used as a solvent, the percutaneous absorbing action thereof is further promoted. The amount of the afore-mentioned compound in the pharmaceutical is within the range of 0.5-50wt.%, preferably 1-20wt.%.
Bipolar affective disorder is a common, severe, chronic and often life-threatening illness. The depressive phase contributes to the majority of morbidity and mortality in this illness. Impairments in physical and social functioning resulting from depression are often as severe as other chronic medical illnesses. Few of the treatments in use have resulted from an understanding of the pathophysiology of bipolar disorder. Undoubtedly, a greater understanding of the pathophysiology of bipolar disorder will lead to improved treatments.

Current theories of depression suggest that mood disorders are associated with impairments of cellular resilience and structural plasticity possibly a result of abnormal cellular energy metabolism. Studies with Magnetic Resonance Spectroscopy (MRS) in bipolar subjects show reduced brain intracellular pH and reduced ATP. Cellular energy generated by mitochondrial oxidative phosphorylation from glucose via the electron transport chain is stored as ATP, which provide neurons and glia with energy required to maintain their function. Mitochondrial dysfunction and its inability to compensate for increase in ATP demand might lead to impaired cellular resilience believed to be involved in the pathophysiology of bipolar disorder. Abnormal regulation of nuclear genes coding for mitochondrial proteins in the hippocampus of bipolar subjects provides further evidence of mitochondrial dysfunction in bipolar disorder.

Coenzyme Q10 (CoQ10) is an essential cofactor in the mitochondrial electron transport chain necessary for cellular energy generation. Exogenous administration of CoQ10 attenuates ATP depletion and has anti-oxidant properties. In light of the above evidence, we hypothesize that bipolar disorder is associated with mitochondrial dysfunction as evidenced by impaired brain energy metabolism and that administration of CoQ10, a mitochondrial enhancer, will restore mitochondrial function. To accomplish these objectives, we will compare mitochondrial functions in bipolar depressed subjects to 26 healthy controls matched for age, gender and BMI. Measures of mitochondrial function will include brain lactate levels (a product of anaerobic glycolysis) with H+ MRS, 2) assays of mitochondrial function in cultured fibroblasts and platelets, and 3) gene expression of mitochondrial and nuclear genes using a cDNA Microarray. Further, subjects with bipolar depression, ages 18 to 65 will be randomized to either CoQ10 (300-1200 mg/day) or placebo in a double-blind placebo controlled trial for a period of 8 weeks. Measures of mitochondrial function will be compared between subjects randomized to placebo or CoQ10 at baseline and at the end of the 8-week trial.
Heart failure (HF) can cause metabolic imbalances, leading to anabolic resistance and increased energy expenditure, which often results in weight loss and cachexia. Comprehensive cardiac rehabilitation (CR), including exercise, nutritional support, and risk management, is crucial for enhancing the health and quality of life of patients with HF and is expected to play a central role in the prevention and treatment of HF-associated cachexia. However, the prevalence of cachexia in patients with HF undergoing comprehensive outpatient CR is currently unknown, and the detailed characteristics including of motor function of such patients remain undefined. Therefore, this cross-sectional study aimed to investigate the prevalence and characteristics of cachexia and the relationship between cachexia and lower limb motor function in patients with HF undergoing outpatient CR. This study included 115 consecutive patients with HF (43% male; mean age, 78 ± 8 years) who underwent comprehensive outpatient CR. The cachexia status was assessed according to the definition proposed by the Asian Working Group on Cachexia in 2023. The Short Physical Performance Battery (SPPB) and Mini Nutritional Assessment Short-Form (MNA-SF) were used to evaluate motor function of the lower limbs and nutritional status, respectively. Multivariate logistic regression analyses were used to examine the potential relationship between cachexia and low SPPB scores (≤ 9 points). The prevalence of cachexia was 30% in this study. Compared with those without cachexia, patients with cachexia were significantly older and showed notable reductions in body mass index, MNA-SF scores, handgrip strength, gait speed, and SPPB scores. A multivariate logistic regression analysis, adjusted for confounders, revealed that both age (odds ratio [OR], 1.129; 95% confidence interval [CI], 1.034-1.248; P = 0.016) and presence of cachexia (OR, 3.783; 95% CI, 1.213-11.796; P = 0.022) were independently associated with low SPPB scores. These findings highlight the importance of focusing on cachexia in patients with HF as part of a comprehensive outpatient CR and may be crucial in developing treatments to improve lower limb motor function in patients with HF who develops cachexia.
To provide a hair cosmetic that can impart softness and elastic feeling to damaged hair.SOLUTION: A hair cosmetic contains components (A) to (C). The component (A) is volatile hydrocarbon. The component (B) is silicone. The component (C) is at least one selected from the group consisting of polyalkylene glycol and ether compounds thereof. The hair cosmetic may further contain a component (D). The component (D) is at least one selected from the group consisting of sterol compounds and ester derivatives thereof.SELECTED DRAWING: None
Fat-soluble vitamins are normally absorbed from the diet through the gastrointestinal tract and incorporated into fat-rich particles called chylomicrons made in the intestinal wall. Chylomicrons are secreted by the intestine into the bloodstream. In a rare lipid metabolic disorder called abetalipoproteinemia, a defect in the assembly of the fat and vitamin containing particles prevents the formation of chylomicrons resulting in the malabsorption of fat and fat-soluble vitamins. A similar assembly defect of fat and fat-soluble vitamins occurs in the liver and prevents the secretion of these particles. Severe fat-soluble vitamin deficiency results even despite mega doses of oral fat-soluble vitamins. Clinically, the subjects develop neurologic and ophthalmologic symptoms similar to those in Vitamin A and E deficiency. This study is designed to determine whether short-term intravenous fat-soluble vitamins and fat emulsion can reverse the neurologic and ophthalmologic complications of fat-soluble vitamin deficiency based on noninvasive procedures routinely employed in clinical practice.
PROBLEM TO BE SOLVED: To obtain a new melanin pigment decomposing substance by using a specific substance having properties capable of acting on a melanin pigment contained in a microorganism, a plant, an animal, etc., and depolymerizing or decomposing the pigment. SOLUTION: An optical semiconductive substance is used. Zinc oxide, titanium dioxide, tungsten oxide, silicone, a polyacetylene, polythiophene, etc., may be cited as the optical semiconductive element. Titanium dioxide is especially preferable. The melanin pigment decomposing effect is improved by further adding a small amount of electroconductive powder to the optical semiconductive substance. Carbon black, silver, copper, etc., may be cited as the electroconductive powder. Tin oxide containing 0.1-20wt.% of antimony oxide is preferable due to high electroconductivity. The amount of the electroconductive substance is preferably about 1-100 pts.wt. based on 100 pts.wt. of the optical semiconductive substance.  When the optical semiconductive substance is coated with a porous substance and used, advantageously deterioration caused by contact of the optical semiconductive substance with a base component can be avoided.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In a 12-week, placebo-controlled clinical study and an open-label extension study (SUPER-1) in 277 sildenafil-treated adults with PAH (WHO Group I) [see Clinical Studies (14)] the adverse reactions that were reported by at least 10% of sildenafil-treated patients in any dosing group, and were more frequent in sildenafil-treated patients than in placebo-treated patients are shown in Table 1. Adverse reactions were generally transient and mild to moderate in nature. The overall frequency of discontinuation in sildenafil-treated patients was 3% (20 mg and 40 mg three times a day) and 8% (80 mg three times a day). The overall frequency of discontinuation for placebo was 3%.

In a placebo-controlled fixed dose titration study (PACES-1) of sildenafil (starting with recommended dose of 20 mg and increased to 40 mg and then 80 mg all three times a day) as an adjunct to intravenous epoprostenol in patients with PAH, no new safety issues were identified except for edema, which occurred in 25% of subjects in the combined sildenafil + epoprostenol group compared with 13% of subjects in the epoprostenol group [see Clinical Studies (14)]. 

Pediatric use information is approved for Viatris Specialty LLC’s, REVATIO (sildenafil) tablets. However, due to Viatris Specialty LLC’s marketing exclusivity rights, this drug product is not labeled with that information.
For the control group the one portable stimulator (Compex 2, Medicompex SA, Ecublens, Switzerland) will be used to apply a stimulation of 15 minutes considered by TENS at the lowest intensity detectable by the participant in order to not influence the outcomes of interest. Our aim is to strengthen IFM which is not the role of TENS. The two electrodes will be placed on the dominant foot, at the same place than those for the NMES group.
Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
A cationic silicone compound which can be employed in a variety of environments, such as a fiber lubricant, textile fabric softener, hair conditioner, and skin conditioner. The cationic silicone is formed from an amino silicone compound which has formula (I), wherein a, b, and c are 0-300; d is 0-4, preferably 1 or 2; R1? comprises hydrogen, an alkyl, aryl, alkynyl, alkenyl, alkyloxyalkylene group which may be unsubtituted or substituted with P, N, or S moieties; R2? is defined the same as R1? and can also be a carboxylic acid residue preferably a fatty acid residues, with the proviso that where R2? is a carboxylic acid residue, the R1? attached to the terminal N is hydrogen; R3? is defined the same as R2? and can also be alkoxy, aryloxy or oxyalkylene groups; R4? is defined the same as R3? and can also be an amino-substituted alkyl group; Z1? and Z2? can be the same or different and comprise an alkyl, aryl, alkenyl or alkynyl group with the proviso that if b is 0, then at least one of the R4? groups comprises an amino-substituted alkyl group. In particular, the aminosilicone is quaternized using known quaternizing agents, e.g., alkylation reagents.
<P>PROBLEM TO BE SOLVED: To provide a product which uses glue, can be produced from materials originated from natural substances not containing an injurious substance in simple production processes, and has excellent moisture retainability, air permeability, adhesiveness and gloss-imparting property, to provide a processed product of earth and sand, and to provide an aqueous solution for tanning leather products.  <P>SOLUTION: Glue, soap and water are mixed and charged in a heat-resistant container. Herein, the mixing weight ratio of glue, soap and water is 1:2 to 3: 10 to 30, preferably 1: 3: 20. Then, the mixture of the glue, the soap and the water is heated to 60 to 80°C, preferably 70°C, to dissolve the mixture. The dissolved mixture is enough stirred to produce the glue product which is a creamy high viscous fluid.  <P>COPYRIGHT: (C)2008,JPO&INPIT
OBJECTIVE: To evaluate the association between a topical hemostatic agent used at the time of cesarean delivery and uterine scar disruption (rupture or dehiscence) at the subsequent trial of labor after cesarean (TOLAC).
METHODS: A multicenter retrospective cohort study was conducted (2005-2021). Parturients with a singleton pregnancy in whom a topical hemostatic agent was placed during the primary cesarean delivery were compared with patients in whom no such agent was placed. We assessed the uterine scar disruption rate after the subsequent TOLAC and the rate of adverse maternal outcomes. Univariate analyses were followed by multivariate analysis (adjusted odds ratio [aOR]; 95% confidence interval [CI]).
RESULTS: During the study period, 7199 women underwent a trial of labor and were eligible for the study; 430 (6.0%) had prior use of a hemostatic agent, 6769 (94.0%) did not. In univariate analysis, a history of topical hemostatic agent use was not found to be significantly associated with uterine scar rupture, dehiscence, or failed trial of labor. This was also confirmed on multivariate analysis for uterine rupture (aOR 1.91, 95% CI 0.66-5.54; P = 0.23), dehiscence of uterine scar (aOR 1.62, 95% CI 0.56-4.68; P = 0.37), and TOLAC failure (aOR 1.08, 95% CI 0.79-1.48; P = 0.61).
CONCLUSION: A history of hemostatic agent use is not associated with an increased risk for uterine scar disruption after subsequent TOLAC. Further prospective studies in other settings are needed to strengthen these findings.
According to sample size calculation 26 patients scheduled for systemic sclerosis will be included. Patients planned for systemic sclerosis will be evaluated twice at the beginning and at the end of the 8th week. The study was planned as a prospective randomized controlled study. Patients will be randomized using a computer program and divided into two groups as telerehabilitation treatment and home exercise group. For the telerehabilitation group, a progressive exercise program video link will be sent over the internet every 2 weeks. The exercise brochure will be explained and sent to the patient group followed up with the home program only at the beginning of the program.
The standard 3+3 Phase 1 trial design will be used for the conduct of this study. Three to six patients can be concurrently enrolled onto a dose level. Accrual is suspended when a cohort of three has been enrolled until toxicity data for that cohort have been reported, or when the study endpoints have been met.
Circular RNAs (circRNAs) are reported to be involved in the tumorigenesis of lung adenocarcinoma (LUAD). Here, this study focused on studying the function and mechanism of circHSPB6 in LUAD progression. Levels of genes and proteins were tested using qRT-PCR and western blotting analyses. The 5-ethynyl-2'-deoxyuridine (EdU), colony formation, flow cytometry, and transwell assays were adopted for in vitro assays. In vivo assay was conducted using mouse xenograft models. The binding between let-7a-2-3p and circHSPB6 or CCL2 was validated using RIP and dual-luciferase reporter assays. The M2 polarization of tumor-associated macrophages (TAMs) was analyzed by flow cytometry. LUAD tissues and cells showed high circHSPB6 expression, knockdown of circHSPB6-suppressed LUAD cell proliferation, migration, invasion, and induced cell apoptosis in vitro, as well as hindered tumor growth in vivo. Mechanistically, circHSPB6/let-7a-2-3p/CCL2 forms a feedback loop. CircHSPB6 could regulate CCL2 expression via sponging let-7a-2-3p. Further rescue assays showed that the effects of circHSPB6 silencing on LUAD cells were reversed by let-7a-2-3p inhibition or CCL2 overexpression. Moreover, circHSPB6 promoted the M2 polarization and infiltration of TAMs by CCL2. Functionally, circHSPB6 knockdown in A549 and H1299 cells inhibited TAM M2 polarization and then suppressed cell proliferation, migration, invasion, and emergency medical technicians (EMT) progression, while these effects were reversed by CCL2 up-regulation CircHSPB6 induced TAM M2 polarization to promote LUAD cell proliferation, migration, invasion, and EMT progression through let-7a-2-3p/CCL2 axis.
The COVID-19 virus pandemic has massively affected us all. We now know there is a much larger proportion of British Black, Asian and minority ethnic (BAME) patients suffering from COVID-19 infections. This disproportionate level of infection and severity of disease has raised concerns and worries. Other research from April 2020 showed that 71% of the nurses and midwives and 94% of the doctors and dentists that died of COVID-19 infections were from a BAME background despite this group representing 20% and 44% of the workforce respectively. The survival picture is also grim for Black and Asian members of the public where we see disproportionately high rates of deaths. Research estimates that our DNA and the environment equally influence the risk for infection. This clinical study plans to better understand our DNA. Some of the things we will be looking at is age, sex, ethnicity and any illnesses such as diabetes or blood pressure. We will ask people for some spit and look at their medical records. This may help us find some of the reasons why this virus has different effects on people and how we might protect people from COVID-19.